Please login to the form below

Not currently logged in

Dr Reddy's enters deal with R-Pharm

India-based Dr Reddy's Laboratories has entered a licensing and development deal with Russian company R-Pharm

India-based Dr Reddy's Laboratories has entered a licensing and development deal with Russian company R-Pharm.

The agreement will see the companies, both based in leading emerging markets, co-develop high technology products and facilitate the sharing of knowledge. Manufacturing techniques will also be exchanged as part of the deal which will work on a profit sharing model.

With a focus on the development and marketing of generic medicines, Dr Reddy's has a global reach in key therapy areas. It first entered the Russian market in 1992.

R-Pharm is mainly focused on the R&D and manufacturing of new products, achieving total revenues of $15.3bn in 2009.

"We are excited about this collaboration as it helps us to deepen our engagement with Russia, one of our key markets," said Satish Reddy, managing director and chief operating officer, Dr. Reddy's. "The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company- RPharm. It will also allow Dr. Reddy's to import and market R-Pharm products in India according to agreed terms."

Alexey Repik, chairman of R-Pharm commented on the impact the deal would have on India-Russia relations: "This agreement helps address unmet medical needs in important therapeutic areas and make medicines more affordable to patients in Russia. It also pioneers a new way of collaboration between an Indian and a Russian pharmaceutical company. It is a change of approach from just imports of finished products to deep integration in technology, manufacturing, marketing and knowledge sharing."

The agreement follows plans announced by Denmark-based Novartis to invest $500m in the Russian pharmaceutical and healthcare industry, including the construction of a manufacturing plant in St Petersburg.

22nd December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...